Yoon‐Koo Kang - Concepedia

Author

Yoon‐Koo Kang

Also Known As

Im‐Ryung Kim, Jeong Hwan Yook, Kang Y, Kang, Y.-K., Kang, Y.K., Kang, Y.K.;Song, J.S.;Hong, S.S.;Kwon, Y.N.;Lee, J.H.;Kim, Y.H.;, Kang, Yoon Koo, Kazuhiko Koike, Korean Gastrointestinal Stromal Tumor Study Group, L.-T Chen

862

Publications

59.5K

Citations

H-Index

154

Concepts

All Affiliations

Asan Medical Center University of Ulsan Ulsan College Samsung Medical Center Sungkyunkwan University

About

Yoon‐Koo Kang is an author at Asan Medical Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	64	194	36.7K
2	Health Sciences	31	44	14.3K
3	Engineering	3	3	227
4	Public Health	1	1	61
5	Social Sciences	1	1	41

Yoon‐Koo Kang

350

Publications

55.8K

Citations

H-Index

Page 1

	Year	Citations
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova, The Lancet Surgical OncologyChemotherapy Versus ChemotherapyGastrointestinal OncologyMedicineGastroenterology	2010	7.2K
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen, The Lancet Oncology HepatologyMedicineCancer ManagementPhase IiiClinical Trials	2008	5.8K
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau, The Lancet HepatologyMedicineExpansion TrialLiver CancerAdvanced Hepatocellular Carcinoma	2017	4.2K
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh, The Lancet Esophageal CancerGastrointestinal OncologyLeast TwoMedicineGastroenterology	2017	2.2K
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, The Lancet Oncology OncologyHepatologyα-Fetoprotein ConcentrationsClinical TrialsPathology	2019	1.6K
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial George D. Demetri, Peter Reichardt, Yoon‐Koo Kang, The Lancet Gastrointestinal OncologyMedicinePharmacologyPathologyPharmacotherapy	2012	1.4K
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo, NEJM Evidence	2022	1.3K
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim, JAMA Oncology	2020	1.2K
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Atsushi Ohtsu, Manish A. Shah, Eric Van Cutsem, Journal of Clinical Oncology	2011	1.1K
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors Muhammad S. Beg, Andrew Brenner, Jasgit C. Sachdev, Investigational New Drugs Tumor BiologyMedicinePathologyAdvanced Solid TumorsExtracellular Microvesicles	2016	855

Page 1